Geminor MP 1 Tablet SR is a combination oral antidiabetic medication containing Glimepiride (1mg), Metformin (500mg), and Pioglitazone (15mg), formulated for sustained release to optimize glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to better glucose uptake in muscle tissues. Pioglitazone, a thiazolidinedione, further enhances insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), leading to improved glucose utilization and lipid metabolism. The combined action of these agents targets multiple pathophysiological defects in type 2 diabetes, offering effective glycemic control while minimizing the risk of hypoglycemia when used appropriately. Geminor MP 1 Tablet SR is indicated as an adjunct to diet and exercise to improve glycemic control in adults inadequately controlled on monotherapy or dual therapy. It is important to monitor renal and hepatic function during treatment and to counsel patients regarding potential side effects such as gastrointestinal disturbances, fluid retention, and hypoglycemia. Dose adjustments may be necessary based on therapeutic response and tolerability.